Provider Newsflash
October, 2021

Company Announcement/Recall – Merck Cubicin

Purpose of this communication:

We are writing to inform you that the FDA has issued notice of a voluntary recall by Merck of one lot of Cubicin (Daptomycin for Injection) 500 mg for IV use, Lot 934778, Exp June 2022 due to the presence of particulate matter (glass) found in the vials.

What do I need to do?

- Please review the following recall notice: https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/merck-issues-voluntary-nationwide-recall-cubicinr-daptomycin-injection-500-mg-lot-934778-due?utm_medium=email&utm_source=govdelivery
- Notify impacted patients and facilitate the repair, replacement and/or resolution of the recall, according to the guidelines issued by the manufacturer in the notification.
- Confirm if you have any CareCentrix patients affected by this recall and notify the CareCentrix Quality Department by faxing information to: 919-792-6718 Attn: Quality Department.

Thank you in advance for your cooperation and continued partnership.